Skip to main content

Table 3 Correlation of ALDH1 with other prognostic markers

From: Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer

Variable Total No (%) ALDH1 (+) No (%) P-value
Total 119 (100) 56 (47)  
Age    0.100
>50 67 (56) 25 (37)  
≤50 52 (44) 31 (59)
T stage    
T1 22 (18) 9 (40)  
T2 78 (65) 38 (49)  
T3 19 (17) 8 (42) 0.985
Nodal status    
Positive 96 (81) 46 (50)  
Negative 23 (19) 8 (38) 0.455
Histological type    
IDC 108 (88.5) 52 (48)  
ILD 11 (11.5) 4 (36) 0.537
Pathological grade    
1 or 2 46 (39) 22 (48)  
3 73 (61) 34 (46) 0.395
Breast cancer subtype    
Luminal A 24 (20) 10 (41)  
Luminal B 49 (40) 20 (41)  
HER2 17 (14) 10 (59)  
TN 29 (24) 16 (55) 0.431
Ki67 (N = 106)    
>20% 68 (64) 29 (58)  
≤20% 38 (36) 21 (42) 0.311
Surgery    
Mastectomy 56 (47) 21 (37)  
BCS 63 (53) 35 (55) 0.066
Response    
pCR 26 (22) 6 (23)  
Non-pCR 93 (78) 50 (54) 0.007
  1. ALDH1, aldehyde dehydrogenase-1; pCR, pathologic complete response; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; TN, triple negative.